Eintrag weiter verarbeiten
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi
Gespeichert in:
| Zeitschriftentitel: | Antimicrobial Agents and Chemotherapy |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , , |
| In: | Antimicrobial Agents and Chemotherapy, 62, 2018, 7 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society for Microbiology
|
| Schlagwörter: |
| author_facet |
Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. |
|---|---|
| author |
Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. |
| spellingShingle |
Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. Antimicrobial Agents and Chemotherapy In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi Infectious Diseases Pharmacology (medical) Pharmacology |
| author_sort |
koetsveld, joris |
| spelling |
Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.00419-18 <jats:title>ABSTRACT</jats:title> <jats:p> <jats:named-content content-type="genus-species">Borrelia miyamotoi</jats:named-content> is an emerging relapsing fever (RF) <jats:named-content content-type="genus-species">Borrelia</jats:named-content> species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates are resistant to amoxicillin <jats:italic>in vitro</jats:italic> ; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> . A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical, <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick, RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> , and <jats:named-content content-type="genus-species">Borrelia burgdorferi</jats:named-content> <jats:named-content content-type="genus-species">sensu lato</jats:named-content> isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains and <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates. All tested RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested <jats:named-content content-type="genus-species">B. burgdorferi sensu lato</jats:named-content> strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains, including <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> are highly susceptible to doxycycline, azithromycin, and ceftriaxone <jats:italic>in vitro</jats:italic> . Interestingly, as described previously for tick isolates, amoxicillin shows poor <jats:italic>in vitro</jats:italic> activity against <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates. </jats:p> <i>In Vitro</i> Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi Antimicrobial Agents and Chemotherapy |
| doi_str_mv |
10.1128/aac.00419-18 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDA0MTktMTg |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDA0MTktMTg |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Rs1 DE-Pl11 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 |
| imprint |
American Society for Microbiology, 2018 |
| imprint_str_mv |
American Society for Microbiology, 2018 |
| issn |
1098-6596 0066-4804 |
| issn_str_mv |
1098-6596 0066-4804 |
| language |
English |
| mega_collection |
American Society for Microbiology (CrossRef) |
| match_str |
koetsveld2018invitroantimicrobialsusceptibilityofclinicalisolatesofborreliamiyamotoi |
| publishDateSort |
2018 |
| publisher |
American Society for Microbiology |
| recordtype |
ai |
| record_format |
ai |
| series |
Antimicrobial Agents and Chemotherapy |
| source_id |
49 |
| title |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_unstemmed |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_full |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_fullStr |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_full_unstemmed |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_short |
In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_sort |
<i>in vitro</i>
antimicrobial susceptibility of clinical isolates of borrelia miyamotoi |
| topic |
Infectious Diseases Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1128/aac.00419-18 |
| publishDate |
2018 |
| physical |
|
| description |
<jats:title>ABSTRACT</jats:title>
<jats:p>
<jats:named-content content-type="genus-species">Borrelia miyamotoi</jats:named-content>
is an emerging relapsing fever (RF)
<jats:named-content content-type="genus-species">Borrelia</jats:named-content>
species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
tick isolates are resistant to amoxicillin
<jats:italic>in vitro</jats:italic>
; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
. A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
clinical,
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
tick, RF
<jats:named-content content-type="genus-species">Borrelia</jats:named-content>
, and
<jats:named-content content-type="genus-species">Borrelia burgdorferi</jats:named-content>
<jats:named-content content-type="genus-species">sensu lato</jats:named-content>
isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF
<jats:named-content content-type="genus-species">Borrelia</jats:named-content>
strains and
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
tick isolates. All tested RF
<jats:named-content content-type="genus-species">Borrelia</jats:named-content>
strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested
<jats:named-content content-type="genus-species">B. burgdorferi sensu lato</jats:named-content>
strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF
<jats:named-content content-type="genus-species">Borrelia</jats:named-content>
strains, including
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
are highly susceptible to doxycycline, azithromycin, and ceftriaxone
<jats:italic>in vitro</jats:italic>
. Interestingly, as described previously for tick isolates, amoxicillin shows poor
<jats:italic>in vitro</jats:italic>
activity against
<jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content>
clinical isolates.
</jats:p> |
| container_issue |
7 |
| container_start_page |
0 |
| container_title |
Antimicrobial Agents and Chemotherapy |
| container_volume |
62 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792334607999303686 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T14:30:51.688Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=In+Vitro++++++++++++Antimicrobial+Susceptibility+of+Clinical+Isolates+of+Borrelia+miyamotoi&rft.date=2018-07-01&genre=article&issn=1098-6596&volume=62&issue=7&jtitle=Antimicrobial+Agents+and+Chemotherapy&atitle=%3Ci%3EIn+Vitro%3C%2Fi%3E%0A++++++++++++Antimicrobial+Susceptibility+of+Clinical+Isolates+of+Borrelia+miyamotoi&aulast=Hovius&aufirst=Joppe+W.&rft_id=info%3Adoi%2F10.1128%2Faac.00419-18&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792334607999303686 |
| author | Koetsveld, Joris, Manger, Annemijn, Hoornstra, Dieuwertje, Draga, Ronald O., Oei, Anneke, Kolyasnikova, Nadezhda M., Toporkova, Marina G., Sarksyan, Denis S., Wagemakers, Alex, Platonov, Alexander E., Hovius, Joppe W. |
| author_facet | Koetsveld, Joris, Manger, Annemijn, Hoornstra, Dieuwertje, Draga, Ronald O., Oei, Anneke, Kolyasnikova, Nadezhda M., Toporkova, Marina G., Sarksyan, Denis S., Wagemakers, Alex, Platonov, Alexander E., Hovius, Joppe W., Koetsveld, Joris, Manger, Annemijn, Hoornstra, Dieuwertje, Draga, Ronald O., Oei, Anneke, Kolyasnikova, Nadezhda M., Toporkova, Marina G., Sarksyan, Denis S., Wagemakers, Alex, Platonov, Alexander E., Hovius, Joppe W. |
| author_sort | koetsveld, joris |
| container_issue | 7 |
| container_start_page | 0 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 62 |
| description | <jats:title>ABSTRACT</jats:title> <jats:p> <jats:named-content content-type="genus-species">Borrelia miyamotoi</jats:named-content> is an emerging relapsing fever (RF) <jats:named-content content-type="genus-species">Borrelia</jats:named-content> species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates are resistant to amoxicillin <jats:italic>in vitro</jats:italic> ; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> . A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical, <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick, RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> , and <jats:named-content content-type="genus-species">Borrelia burgdorferi</jats:named-content> <jats:named-content content-type="genus-species">sensu lato</jats:named-content> isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains and <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates. All tested RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested <jats:named-content content-type="genus-species">B. burgdorferi sensu lato</jats:named-content> strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains, including <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> are highly susceptible to doxycycline, azithromycin, and ceftriaxone <jats:italic>in vitro</jats:italic> . Interestingly, as described previously for tick isolates, amoxicillin shows poor <jats:italic>in vitro</jats:italic> activity against <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates. </jats:p> |
| doi_str_mv | 10.1128/aac.00419-18 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDA0MTktMTg |
| imprint | American Society for Microbiology, 2018 |
| imprint_str_mv | American Society for Microbiology, 2018 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Rs1, DE-Pl11, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161 |
| issn | 1098-6596, 0066-4804 |
| issn_str_mv | 1098-6596, 0066-4804 |
| language | English |
| last_indexed | 2024-03-01T14:30:51.688Z |
| match_str | koetsveld2018invitroantimicrobialsusceptibilityofclinicalisolatesofborreliamiyamotoi |
| mega_collection | American Society for Microbiology (CrossRef) |
| physical | |
| publishDate | 2018 |
| publishDateSort | 2018 |
| publisher | American Society for Microbiology |
| record_format | ai |
| recordtype | ai |
| series | Antimicrobial Agents and Chemotherapy |
| source_id | 49 |
| spelling | Koetsveld, Joris Manger, Annemijn Hoornstra, Dieuwertje Draga, Ronald O. Oei, Anneke Kolyasnikova, Nadezhda M. Toporkova, Marina G. Sarksyan, Denis S. Wagemakers, Alex Platonov, Alexander E. Hovius, Joppe W. 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.00419-18 <jats:title>ABSTRACT</jats:title> <jats:p> <jats:named-content content-type="genus-species">Borrelia miyamotoi</jats:named-content> is an emerging relapsing fever (RF) <jats:named-content content-type="genus-species">Borrelia</jats:named-content> species that is reported to cause human disease in regions in which Lyme borreliosis is endemic. We recently showed that <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates are resistant to amoxicillin <jats:italic>in vitro</jats:italic> ; however, clinical isolates have not been studied. Therefore, our aim was to show the antimicrobial susceptibility of recently obtained clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> . A dilution series of various antibiotics was made in modified Kelly-Pettenkofer medium with 10% fetal calf serum. The susceptibilities of different <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical, <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick, RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> , and <jats:named-content content-type="genus-species">Borrelia burgdorferi</jats:named-content> <jats:named-content content-type="genus-species">sensu lato</jats:named-content> isolates were tested by measuring MICs through colorimetric changes and by counting motile spirochetes by dark-field microscopy after 72 h of incubation. The ceftriaxone and azithromycin MIC ranges of the six <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates tested were 0.03 to 0.06 mg/liter and 0.0016 to 0.0032 mg/liter, respectively. These values are similar to MICs for RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains and <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> tick isolates. All tested RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains were susceptible to doxycycline (microscopic MIC range, 0.0625 to 0.25 mg/liter). In contrast to the MICs of the tested <jats:named-content content-type="genus-species">B. burgdorferi sensu lato</jats:named-content> strains and in line with our previous findings, the amoxicillin MICs (range, 8 to 32 mg/liter) of all RF <jats:named-content content-type="genus-species">Borrelia</jats:named-content> strains, including <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates, were above the clinical breakpoint for resistance (≤4 mg/liter). Clinical isolates of <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> are highly susceptible to doxycycline, azithromycin, and ceftriaxone <jats:italic>in vitro</jats:italic> . Interestingly, as described previously for tick isolates, amoxicillin shows poor <jats:italic>in vitro</jats:italic> activity against <jats:named-content content-type="genus-species">B. miyamotoi</jats:named-content> clinical isolates. </jats:p> <i>In Vitro</i> Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi Antimicrobial Agents and Chemotherapy |
| spellingShingle | Koetsveld, Joris, Manger, Annemijn, Hoornstra, Dieuwertje, Draga, Ronald O., Oei, Anneke, Kolyasnikova, Nadezhda M., Toporkova, Marina G., Sarksyan, Denis S., Wagemakers, Alex, Platonov, Alexander E., Hovius, Joppe W., Antimicrobial Agents and Chemotherapy, In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi, Infectious Diseases, Pharmacology (medical), Pharmacology |
| title | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_full | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_fullStr | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_full_unstemmed | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_short | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| title_sort | <i>in vitro</i> antimicrobial susceptibility of clinical isolates of borrelia miyamotoi |
| title_unstemmed | In Vitro Antimicrobial Susceptibility of Clinical Isolates of Borrelia miyamotoi |
| topic | Infectious Diseases, Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1128/aac.00419-18 |